Clinical trials: Primary
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Trial name
- ELUCIDATE (NCT05985655)
- Testing
- GTAEXS617, SoC
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 230 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Primary IgA Nephropathy
A Trial of HR19042 Capsule in Healthy Chinese Subjects
The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects.
- Trial name
- NCT04887532
- Testing
- HR19042 capsule
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Methamphetamine Abuse
Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder
The overall purpose of the observational, investigational pilot study is to assess the clinical utility of the Affect digital health platform (the Affect® "app") as part of the Affect program of treatment for…
- Trial name
- NCT05266716
- Testing
- Affect Methamphetamine Treatment Program
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Affect Therapeutics, Inc.
Primary Hypercholesterolemia
An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe
The study observes real world patients with primary hypercholesterolemia who receive a fixed dose combination therapy with atorvastatin and ezetimibe for 24 weeks; collects and analyzes data related to efficacy and safety of the…
- Trial name
- LITE (NCT05559606)
- Where
- South Korea
- Volunteers
- 1,839 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hereditary Angioedema, HAE
Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE who live in…
- Trial name
- APeX-J (NCT03873116)
- Testing
- BCX7353 capsules
- Where
- 10 sites in Japan
- Volunteers
- 19 people
- Sponsor
- BioCryst Pharmaceuticals
IgAN
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients.
- Trial name
- NCT07606352
- Testing
- STL303
- Where
- 8 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Sitala Bio LTD
Primary Biliary Cholangitis, Compensated Cirrhosis
An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Participants with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
- Conditions
- Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
- Trial name
- NCT04950764
- Testing
- Seladelpar
- Where
- 20 sites in United States, South Korea and 2 more
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Recurrent Glioblastoma, Brain Tumor
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.
- Trial name
- NCT00503204
- Testing
- Cediranib, Lomustine
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Primary Biliary Cholangitis
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).
- Trial name
- NCT05239468
- Testing
- Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg
- Where
- 26 sites in United States, Argentina and 2 more
- Volunteers
- 72 people
- Sponsor
- Intercept Pharmaceuticals
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer
Neoplasms, Liver
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
The primary purpose of this study is to determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 (Pexa-Vec) injected within hepatic carcinoma tumors.
- Trial name
- NCT00629759
- Testing
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Jennerex Biotherapeutics
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
The purpose of this study is to determine whether a fixed-dose combination of naratriptan 2,5 mg + naproxen 500 mg is effective and safe compared each monotherapy for the acute treatment of migraine.
- Trial name
- Copérnico (NCT01726920)
- Testing
- naratriptan + naproxen, naratriptan, naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL)
- Trial name
- NCT06014762
- Testing
- P-CD19CD20-ALLO1, Rimiducid
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Poseida Therapeutics, Inc.
Nocturnal Enuresis
MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis
Desmopressin in treatment of nocturnal enuresis (bedwetting).
- Trial name
- MELT (NCT01368913)
- Where
- 73 sites in Germany
- Volunteers
- 138 people
- Sponsor
- Ferring Pharmaceuticals
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a…
- Trial name
- FIRCE-1 (NCT05972720)
- Testing
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Where
- 31 sites in United States
- Volunteers
- 101 people
- Sponsor
- CARGO Therapeutics
Primary Axillary Hyperhidrosis
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis
The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions.
- Trial name
- NCT04159610
- Testing
- WO3970, Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Primary Open Angle Glaucoma
Multicenter Glaucoma Study Investigating Standalone Canaloplasty
A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight…
- Trial name
- MAGIC (NCT05786196)
- Testing
- Ab-interno canaloplasty utilizing the iTrack Advance device, Ab-interno canaloplasty utilizing the OMNI Surgical System
- Where
- 5 sites in Germany, Spain and 1 more
- Volunteers
- 86 people
- Sponsor
- Nova Eye, Inc.
Myelofibrosis
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of…
- Trial name
- NCT06024915
- Testing
- TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Migraine
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
- Trial name
- AURORA (NCT06602479)
- Testing
- MEDI0618
- Where
- 71 sites in United States, Czechia and 6 more
- Volunteers
- 309 people
- Sponsor
- AbbVie
Primary Parathyroid Adenomas
Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure
This study is a multicentre, open, uncontrolled trial for the observation of histological changes in parathyroid adenomas following high intensity focused ultrasound (HIFU).
- Trial name
- NCT01060982
- Testing
- Ultrasonic ablation device
- Where
- 2 sites in France
- Volunteers
- 5 people
- Sponsor
- Theraclion
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.